
TriSalus Life Sciences, Inc.: updates and filings
Price
$2.32
November 20, 2026Market cap $142M
What Ploutos Investor adds for TriSalus Life Sciences
Part of Ploutos Investor, €9.99 a month
- The full history: 4 fiscal years, from 2022
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 10, 2026next Feb 10, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
September 2026
August 2026
May 2026
April 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 10, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 10, 2026Results of operationsForm8-K
- Sep 22, 2026Other material eventsForm8-K
- Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 6, 2026Results of operationsForm8-K
- Jul 7, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 20, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 15, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 14, 2026Shareholder voteForm8-K
- May 12, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 12, 2026Results of operationsForm8-K
- May 12, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 29, 2026Officer or director changeForm8-K
- Apr 7, 2026Officer or director change, Regulation FD disclosureForm8-K
- Mar 31, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Mar 31, 2026Additional annual meeting materialFormDEFA14A
- Mar 31, 2026Annual meeting proxy statementFormDEF 14A
- Mar 10, 2026Shares registered for employeesFormS-8
- Mar 5, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 5, 2026Results of operationsForm8-K
- Feb 20, 2026Material agreement entered, other material eventsForm8-K
- Feb 9, 2026Officer or director change, Regulation FD disclosureForm8-K
- Jan 12, 2026Results of operationsForm8-K
- Dec 4, 2025FilingFormEFFECT
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 10, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 10, 2026 | 8-K | Results of operations | Document |
| Sep 22, 2026 | 8-K | Other material events | Document |
| Aug 6, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 6, 2026 | 8-K | Results of operations | Document |
| Jul 7, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 20, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 15, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 14, 2026 | 8-K | Shareholder vote | Document |
| May 12, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 12, 2026 | 8-K | Results of operations | Document |
| May 12, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 29, 2026 | 8-K | Officer or director change | Document |
| Apr 7, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| Mar 31, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Mar 31, 2026 | DEFA14A | Additional annual meeting material | Document |
| Mar 31, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Mar 10, 2026 | S-8 | Shares registered for employees | Document |
| Mar 5, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 5, 2026 | 8-K | Results of operations | Document |
| Feb 20, 2026 | 8-K | Material agreement entered, other material events | Document |
| Feb 9, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| Jan 12, 2026 | 8-K | Results of operations | Document |
| Dec 4, 2025 | EFFECT | Filing | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Oct 29, 2020.
The full analysis
What do TriSalus Life Sciences's filings show?
The filings are where every one of TriSalus Life Sciences's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.